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ABSTRACT
Although the promoters of both the Bax and p21
genes are activated by p53, they differ in the effect
on this activation of the POU family transcription
factor Brn-3a. Thus, Brn-3a inhibits activation of the
Bax promoter by p53 but enhances the ability of p53
to activate the p21 promoter. We demonstrate that
repression of p53-mediated activation of the Bax
promoter involves a complex upstream sequence in
which two Brn-3a response elements ¯ank the p53
response element. In contrast, a minimal p21 pro-
moter is activated by Brn-3a and such activation
cannot be abolished without abolishing basal pro-
moter activity. Moreover, synergistic activation by
Brn-3a and p53 continues to be observed when the
p53-binding sites in the p21 promoter are substi-
tuted by the Bax p53 site or by the region of the Bax
promoter essential for Brn-3a-mediated repression,
indicating that the p21 core promoter plays a central
role in this response. The signi®cance of these
effects is discussed in terms of the different
responses of the Bax and p21 promoters and the
overlapping but distinct roles of Brn-3a and p53 in
neuronal growth arrest and apoptosis.
INTRODUCTION
The POU family transcription factor Brn-3a plays a key role in
the survival of speci®c neuronal cell types during develop-
ment. Thus, inhibition of Brn-3a expression using an anti-
sense approach results in the death of sensory neurones in
culture even in the presence of neurotrophic factors (1).
Similarly, knock-out mice lacking a functional gene for Brn-
3a show extensive losses of somato-sensory neurones with
resulting death of the animal soon after birth (2,3).
Conversely, over-expression of Brn-3a in sensory (1,4) or
central nervous system (5) neurones protects them from
stimuli which would otherwise induce death. Most import-
antly, this effect has also been observed in vivo where over-
expression of Brn-3a with a viral vector protected neonatal
sensory neurones from the death-inducing effects of sciatic
nerve lesion (6).
Interestingly, in addition to its effects on neuronal survival,
Brn-3a also has effects on neuronal differentiation. Thus,
expression of Brn-3a de®nes the earliest post-mitotic neurones
to appear in the central nervous system (7) and defects in the
outgrowth of sensory neurone axons precede cell death in
mice lacking Brn-3a (8). Similarly, we have demonstrated
that differentiation (involving growth arrest and neurite
outgrowth) in a neuronal cell line is accompanied by enhanced
expression of Brn-3a (9) and that arti®cial over-expression of
Brn-3a in this cell line can induce neuronal differentiation in
the absence of stimuli which would normally induce it (10).
The effects of Brn-3a on neuronal survival and neuronal
differentiation require distinct features of the molecule. Thus,
differentiation can be induced by over-expression of the
isolated C-terminal POU domain of Brn-3a alone (10) and this
domain is suf®cient for the transcriptional activation of a
number of genes involved in neuronal differentiation such as
SNAP25 and the neuro®lament genes (10±12). Hence, this
domain can act as a transcription activation domain as well as
acting as a DNA-binding domain. In contrast however,
protection of neuronal cells from apoptosis requires not only
the POU domain of Brn-3a but also an additional N-terminal
domain which is present in only one of the two forms of Brn-
3a. Hence, only the long form of Brn-3a which contains this
domain can induce protection from cell death-inducing stimuli
whereas the short form which lacks this domain cannot do so
(13). Similarly, the POU domain is insuf®cient for the
activation by Brn-3a of genes encoding factors such as
Bcl-2 and Bcl-x which have a protective effect against cell
death (4,13,14).
Hence, two distinct types of promoters activated by Brn-3a
exist with some, such as the neuro®laments and SNAP25,
requiring only the POU domain of Brn-3a for their activation
whereas others such as Bcl-2 require in addition the
N-terminal domain. Interestingly, promoters activated by
Brn-3a also differ in the nature of the sequences required for
their transcriptional activation. Thus, some promoters, such as
those of the genes encoding SNAP25 and Bcl-2, contain
distinct upstream binding sites for Brn-3a which are essential
for the transcriptional activation response (4,11). In contrast,
in a number of other promoters the sequences required for the
response to Brn-3a cannot be dissected away from the basal
promoter sequence, with activation by Brn-3a being lost in a
deletion analysis at the same point as basal promoter activity.
Promoters of this type include those of the genes encoding
*To whom correspondence should be addressed. Tel: +44 20 7905 2189; Fax: +44 20 7242 8437; Email: d.latchman@ich.ucl.ac.uk



























































































 Bcl-x and the neuro®laments (12,14). Hence, Brn-3a-activated
promoters differ in both their requirement for the N-terminus
of Brn-3a and in the nature of the sequences required for the
response to either the N-terminal domain or the isolated POU
domain.
We have previously demonstrated in the case of both the
Bcl-2 and Bcl-x promoters that transcriptional activation by
Brn-3a is inhibited by over-expression of the pro-apoptotic
p53 protein (14,15). Interestingly, however, once again these
two promoters differ in the nature of the sequences required
for p53-mediated repression. Thus, in the case of the Bcl-2
promoter, a p53-binding site located approximately 50 bases
away from the Brn-3a-binding site in the upstream region of
the promoter (over 500 bases upstream from the transcrip-
tional start site) is required for transcriptional repression by
p53 (15). Conversely, in the Bcl-x promoter a minimal basal
promoter remains responsive to activation by Brn-3a and such
activation is inhibited by p53 even on a minimal promoter
construct (14). Hence, repression by p53 of the Bcl-2 and
Bcl-x promoters requires, respectively, upstream sequences
and basal promoter elements paralleling the distinct
requirements for activation by Brn-3a on these two promoters.
We have recently demonstrated that antagonism between
Brn-3a and p53 is also observed on the promoter of the pro-
apoptotic Bax gene with Brn-3a inhibiting transcriptional
activation of this promoter by p53 (16). Interestingly,
however, a distinct effect is observed on the promoter of the
cell cycle arrest gene p21 which is also activated by p53. Thus,
on this promoter p53 and Brn-3a co-operate together to induce
enhanced activation of the promoter compared to either factor
alone (16).
In view of the complex responses to Brn-3a observed on
Brn-3a-activated promoters, we wished to investigate the
nature of the promoter sequences required for regulation by
Brn-3a on these two p53-activated promoters in order to
understand the distinct interaction between Brn-3a and p53
which occurs on these two different promoters.
MATERIALS AND METHODS
Bax and p21 promoter constructs
p21-2326, p21-587, p21-144, p21-94 vectors were a kind gift
from Dr W. El-Deiry (17,18). The Bax full-length promoter
construct was a kind gift from Dr J. Reed (19). The Bax-afe
construct was obtained by removing the fragment between the
PstI and AfeI restriction sites from the Bax full-lengthplasmid.
The Bax-mut and Bax-afe-mut constructs were obtained from
the Bax full-length and Bax-afe plasmids, respectively. The
Brn-3a responsive element (RE) located between ±71 and ±64
from the start site of transcription in the Bax promoter was
mutated in both plasmids using the site-directed mutagenesis
kit (Stratagene). Double-mut-bax construct was obtained by
mutating a Brn-3a RE upstream to the p53 site, located
between ±166 and ±155 from the start site of transcription. To
obtain mixBaxp21, the fragment between positions ±136 and
±42 in the Bax promoter was isolated by digesting the Bax
full-length construct with DdeI restriction enzyme and was
cloned in front of the ±94 bp minimal promoter of p21.
Wwp (Bsl + Bax), Wwp (Bax + Bs2) and Wwp (Bax + Bax)
vectors contain the p21 promoter but have either one or both of
the p53 original sites replaced by the Bax promoter p53 site.
Bax (Bs1), Bax (Bs2) and Bax (Bs1 + Bs2) vectors contain the
human Bax promoter but the original p53 site was replaced by
p53 site from the p21 promoter. These constructs were a kind
gift from Dr E. Stanbridge (20).
p21 mut 3, p21 mut 4 and p21 mut 5,6 vectors included the
p21 promoter from ±2326 to +16 position but the Sp1 sites
located at ±82 to ±77, ±69 to ±64 and ±60 to ±50 (from the
start site of transcription) were respectively mutated in
each construct. These constructs were a kind gift from
Dr D. Kardassis (21).
Site-directed mutagenesis
The site-directed mutagenesis kit from Stratagene was used to
mutate one or both of the Brn-3a REs from the Bax promoter.
The Bax full-length and Bax-afe plasmids were ampli®ed by
PCR with the following primers which included the mutation
in the downstream Brn-3a RE: 5¢-GGC TAT ATT GCT AGC
GCG CGG TCT CTG CAA AAA AC-3¢;5 ¢-GTT TTT TGC
AGA GAC CGC GCG CTA GCA ATA TAG CC-5¢.
The PCR product was digested with DpnI endonuclease to
degradespeci®callytheparentalDNAtemplate.Thisdigestion
was transformed into XL-1 Blue super-competent cells. In a
similar way, double-mut-bax construct was obtained from the
Bax-mut construct. Bax-mut construct was ampli®ed by PCR
with the following primers which included the mutation in the
upstream Brn-3a RE: 5¢-GCG GTA GCT CGA GCC TGT
AATC-3¢;5 ¢-GAT TAC AGG CTC GAG CTA CCGC-3¢.
Transfection
The ND7 neuronal cell line (22) was grown in L-15 medium
(Gibco) supplemented with 0.35% glucose, 10% fetal calf
serum, 0.35% sodium bicarbonate and 200 mM glutamine. The
cells were transfected by the calcium-phosphate method (23).
Routinely, 0.7 3 105 cells were plated in 24-well plates. Two
hours before transfection the medium was changed to
Dulbecco's modi®ed Eagle's medium (DMEM; Gibco) sup-
plemented with 10% serum. Subsequently, 0.4 mg of reporter
plasmid, 0.4 mg of Brn-3a expression vector and 0.01 mgo f
p53 expression vector plus 0.02 mg of the TK-Renilla plasmid
(Promega) were transfected per well. Sonicated herring sperm
DNA was added to obtain 4 mg of total DNA per well. Four
hours after adding the precipitate, DMEM medium was
changed again to L.15. Cells were harvested after 48 h. Each
transfection was performed at least in triplicate.
Luciferase assays
Transfected cells were lysed in 100 ml/well of 13 passive lysis
buffer (Promega) and 50 ml from each lysate was used to
measure ®re¯y and Renilla luciferase activities. Both
luciferase assays were quanti®ed using a commercially
available kit (Promega) and a TD-20e Luminometer. Values
for ®re¯y luciferase were divided by their corresponding
Renilla luciferase values to obtain relative luciferase units
(RLU). Reporter vector RLU was set at 100.
RESULTS
To analyse the response of the p21 promoter to Brn-3a and p53
we used a series of p21 promoter constructs containing
progressively shorter upstream regions of the p21 promoter



























































































 linked to a luciferase reporter gene (17,18). These constructs
were transfected with Brn-3a and p53 expression vectors.
In these experiments (Fig. 1), the full-length promoter was
activated both by Brn-3a and, to a greater extent, by p53 with
the two factors together producing an enhanced level of
activation compared to either factor alone in accordance with
our previous results (16). This effect was speci®c to Brn-3a
since the related POU family transcription factor Brn-3b failed
to activate the p21 promoter and did not synergise with p53
(data not shown). As expected, deletion of the upstream region
of the promoter containing two p53-binding sites resulted in a
loss of activation by p53 in the construct containing 587 bases
of upstream sequence and in the other, shorter, constructs
(Fig. 1). However, transcriptional activation by Brn-3a con-
tinued to be observed with a construct containing only 94 bases
of upstream sequence of the p21 promoter (Fig. 1). With this
construct, activation by Brn-3a was actually reduced by p53,
possibly due to a non-speci®c squelching effect in the absence
of p53-binding sites. Activation by Brn-3a was only lost when
the promoter was deleted so that it contained only 60 bases of
upstream sequence. This promoter was not responsive to Brn-
3abutalsoshowednobasalactivityindicatingthattheresponse
to Brn-3a could not be dissected away from the basal activity.
Hence, the p21 promoter represents one class of Brn-3a-
activated promoters in which the sequences required for
Brn-3a activation cannot be dissected away from basal
promoter sequences. Evidently, however, the synergistic
effect with p53 requires the presence of upstream p53-binding
sites in the promoter and is lost when these sites are deleted.
The p21 promoter region from ±94 to +16 contains four
binding sites for the Sp1 transcription factor (known as sites
3±6). To assess whether these sites play any role in the
response to Brn-3a or in its interaction with p53, we used
constructs in which each of these sites has been mutated in the
context of the full-length p21 promoter (21). As shown in
Figure 2, all these constructs continued to respond to Brn-3a
and to show stronger activation with Brn-3a and p53 than with
either factor alone, although there was some difference in the
degree of synergy observed with each construct. Hence, none
of these Spl-binding sites is essential for the response to
Brn-3a.
To investigate the nature of the regions of Brn-3a required
for activation of the p21 promoter and for positive functional
interaction with p53, we tested whether the isolated POU
domain of Brn-3a was able to activate the promoter and to
functionally interact with p53. As illustrated in Figure 3, the
isolated POU domain was indeed able to activate the full-
length p21 promoter and to produce stronger transcriptional
activation together with p53 than was observed with either
factor alone. Similarly, the isolated POU domain was able to
activate a minimal p21 promoter containing only 94 bases of
upstream sequence in the same manner as occurred for full-
length Brn-3a. As in the case of full-length Brn-3a, the p21-94
promoter did not exhibit enhanced activation by p53 and the
Brn-3a POU domain together since it lacks p53-binding sites.
Indeed activation by the Brn-3a POU domain was reduced by
p53 (Fig. 3) as was observed for full-length Brn-3a (Fig. 1).
Hence, the p21 promoter represents a Brn-3a-inducible
promoter where induction is dependent on basal promoter
sequences and upon the isolated POU domain alone.
Similarly, functional interaction with p53 on this promoter
requires the p53-binding sites in the promoter and the Brn-3a
POU domain which has previously been shown to be the
region which interacts with p53 via a protein±protein
interaction (15).
In contrast to the p21 promoter, the Bax promoter contains a
single upstream binding site for p53 which has been shown to
be essential for its transcriptional induction by p53 (19). In a
combined deletion/mutation analysis, we identi®ed two sites,
respectively, upstream and downstream of this p53 site which
were essential for the inhibition of p53-mediated activation by
Brn-3a (for details of constructs used in this analysis see
Fig. 4). As expected, the full-length Bax promoter was
strongly inducible by p53 and this induction was reduced by
Brn-3a (Fig. 5A) in accordance with our previous results (16).
Deletion of the region upstream of the p53 site in the construct
Bax-afe resulted in a construct that continued to be inducible
by p53 and was also repressible by Brn-3a (Fig. 5B) (P <
0.01). However, further mutation of a site downstream of the
p53 site within the Bax-afe construct resulted in a construct
(Bax-afe-mut) that continued to be induced by p53 but which
was not repressible by Brn-3a (Fig. 5D).
Hence, this site downstream of the p53 site is involved in
repression by Brn-3a. However, this site does not act alone
Figure 1. Luciferase assay of p21 promoter constructs, co-transfected with
either empty expression vector (V) or expression vectors encoding p53 or
Brn-3a. p21 promoter constructs contain the region of the promoter
beginning at the upstream site indicated in each panel and ending at +16
relative to the transcriptional start site. Values are the mean of at least three
independent determinations whose standard deviation is shown by the bars.



























































































 since its mutation within the context of the full-length Bax
promoter (Bax-mut) resulted in a construct that was still
repressible by Brn-3a (Fig. 5C). Thus, abolition of repression
by Brn-3a requires not only mutation of this downstream site
but also of the region of the promoter upstream of the p53 site.
This dependence on the upstream region was explained by
further mutation of another site upstream of the p53 site. When
this site is mutated together with the downstream site, in the
construct double-mut-bax, then repression by Brn-3a is
abolished (Fig. 5E).
Hence, repression by Brn-3a requires the presence of two
Brn-3a response elements within the Bax promoter which are,
respectively, upstream and downstream of the p53 site.
Inactivation of both of these sites either by mutation or
deletion results in a promoter that is still inducible by p53 but
where this inducibility is not reduced by Brn-3a. In contrast,
mutationor deletion of either site alone results in a promoter in
which induction by p53 can still be repressed by Brn-3a.
Although both these sites were identi®ed in the Bax promoter
during deletion analysis by virtue of their resemblance to
consensus binding sites for Brn-3a (24), we were unable to
detect binding of Brn-3a to these sites using DNA mobility
shift assays in the presence or absence of p53 (data not
shown). It is possible, therefore, that Brn-3a exerts its effect
Figure 2. (A) Sequence of the p21 promoter from ±94 to ±43 showing the Spl-binding sites and their inactivation in the mutant constructs. (B) Luciferase
assay showing the results of co-transfecting p21 constructs containing the full-length promoter with a mutation in the indicated Sp1 site, with either empty
expression vector or expression vectors encoding Brn-3a or p53. Values are the mean of at least three independent determinations whose standard deviation is
shown by the bars.
Figure 3. Luciferase assay showing the result of transfecting the full-length
p21 promoter (A) or the ±94 promoter (B) with empty expression vector (V)
or the same vector encoding either the isolated POU domain of Brn-3a or
p53. Values are the mean of at least three independent determinations
whose standard deviation is shown by the bars.



























































































 by binding to other factors which are already bound to these
sites or alternatively that it binds to the sites with binding
characteristics which are not amenable to detection by DNA
mobility shift assays.
To further probe the features of Brn-3a that are required for
repression of p53 inducibility, we determined whether the
isolated POU domain was able to repress induction by p53 in
the context of the full-length Bax promoter. As illustrated
in Figure 6, this was not the case with the POU domain
being unable to repress induction of the promoter by p53.
Hence, repression of p53 induction on the Bax promoter
requires a region of Brn-3a outside the POU domain, although
the POU domain is necessary and suf®cient for induction of
the p21 promoter and co-operation with p53 on the p21
promoter.
To further investigate the different responses of the two
promoters, we investigated the effect of exchanging the p53-
binding sites in the two promoters. Thus, each of the two p53-
binding sites in the p21 promoter was replaced by the binding
site from the Bax promoter either individually or together (20)
(Fig. 7). Each of these constructs was induced by both p53 and
by Brn-3a, with maximal activation being observed with the
two factors together (Fig. 7) (P < 0.02). Hence, the p21
promoter continues to show a synergistic activation by p53
and Brn-3a even when its p53-binding sites are substituted
with the p53-binding site from the Bax promoter.
However, a different result was observed when the p53-
binding site in the Bax promoter was replaced by one or both
of the binding sites from the p21 promoter (Fig. 8). In this
case, strong activation by p53 continued to be observed but
this was either unaffected or actually increased by addition of
Brn-3a, in contrast to the inhibition of activation produced by
Brn-3a on the intact promoter. This effect was observed
despite the fact that all the constructs contained the Brn-3a
response element downstream of the p53-binding site which is
suf®cient for repression of p53-mediated activation on the
intact Bax promoter.
Hence, it appears that the p53-binding site from the Bax
promoter together with the adjacent downstream Brn-3a
response element are both required for the repression of
p53-mediated activation by Brn-3a. To investigate this effect
further, we linked the p53 site from the Bax promoter together
with the adjacent Brn-3a response element to the minimal
p21 promoter containing 94 bases of upstream regulatory
Figure 4. Bax promoter constructs used in this study and their response to Brn-3a. The position of the p53 site is shown by the box and the position of the
two Brn-3a response elements (Brn-3a RE) by the ovals. A star indicates a mutated Brn-3a response element.
Figure 5. Luciferase assay showing the response of different Bax promoter
constructs (illustrated in Fig. 4) when transfected with empty expression
vector (V) or the same vector encoding either p53 or Brn-3a. Values are the
mean of at least three independent determinations whose standard deviation
is shown by the bars.



























































































 sequence. As illustrated in Figure 1 the ±94 base pair p21
promoter construct retains inducibility by Brn-3a but is not
inducible by p53 due to the absence of p53-binding sites. As
indicated in Figure 9, the addition of the Bax p53-binding site
rendered this promoter inducible by p53 (P < 0.05). Most
importantly, very strong co-operation between Brn-3a and p53
was observed on this promoter construct with activation in the
presence of both factors being much greater than with either
factor alone.
Hence, the combination of the Brn-3a inducible minimal
p21 promoter with an upstream p53-binding site produces
strong synergistic activation of transcription even when
the two elements are separated by a Brn-3a response
element which normally produces inhibition of p53-mediated
transcriptional activation.
DISCUSSION
In several Brn-3a-inducible promoters, it has proved possible
to de®ne upstream binding sites for Brn-3a within the
promoter which are necessary for Brn-3a-mediated induction
of the promoter (4,11,25). In other promoters, however, it has
proved impossible to delete putative regions involved in
mediating Brn-3a inducibility without destroying the basal
activity of the promoter (12,14,26).
Here, we demonstrate that the p21 promoter falls into this
second class of Brn-3a inducible promoters since we were not
able to eliminate Brn-3a inducibility without completely
inactivating the promoter. Moreover, this characteristic of the
p21 promoter appears to be crucial to the manner in which it
responds to Brn-3a and p53 when the two factors are present
together. Thus, co-operation between Brn-3a and p53 on this
promoter is observed not only with its natural p53-binding
sites but also when these sites are substituted with that of the
Bax promoter. Moreover, co-operation between p53 and Brn-
3a is observed even when the minimal p21 promoter is linked
to the p53-binding site from the Bax promoter but the two
elements are separated by a Brn-3a response element from the
Bax promoter which normally produces inhibition of p53-
mediated transactivation. Hence, the characteristics of the core
p21 promoter predominate even in the presence of upstream
elements from the Bax promoter which are normally suf®cient
to produce Brn-3a-mediated repression of p53 transactivation.
The ±94 to +16 p21 promoter which responds to Brn-3a
contains multiple binding sites for the Sp1 transcription factor.
However, mutation of each of these sites within the full-length
p21 promoter did not affect its response to Brn-3a or the
functional interaction of Brn-3a with p53. Hence, the response
to Brn-3a does not appear to depend on the known transcrip-
tion factor binding sites within the minimal responsive p21
Figure 7. (A) Schematic diagram of p21 promoter constructs in which the p53-binding sites (Bs1 and Bs2) have been replaced either individually or together
with the p53-binding site from the Bax promoter. (B) Luciferase assay showing the responses of the different promoter constructs when co-transfected with
empty expression vector (V) or the same vector expressing either p53 or Brn-3a. Values are the mean of at least three independent determinations whose
standard deviation is shown by the bars.
Figure 6. Luciferase assay showing the result of transfecting the full-length
Bax promoter construct with either empty expression vector (V) or expres-
sion vectors encoding p53 or the isolated POU domain of Brn-3a. Values
are the mean of at least three independent determinations whose standard
deviation is shown by the bars.



























































































 promoter. It would be of interest, however, to determine
whether mutations in the Sp1 sites would have any effect in
the context of the minimal p21 promoter linked to the Bax
upstream element.
The ability of Brn-3a to activate the minimal p21 promoter
in an Sp1-independent manner together with the identi®cation
of several other Brn-3a-inducible core promoters (12,14,26)
suggests that Brn-3a may join the basal transcriptional
complex of RNA polymerase II and associated factors on
certain promoters and that the response to other factors is
therefore determined by their interaction with this basal
complex containing Brn-3a. Hence, on the p21 promoter, p53
bound at any upstream site would be able to interact with Brn-
3a in the basal complex via the protein±protein interaction
which we have demonstrated previously (15) and induce
activation. This would occur even in the presence of other
upstream elements which normally would produce repression
of p53-mediated transactivation.
In contrast to the relatively simple situation on the p21
promoter where the core promoter determines its character-
istics, the situation on the Bax promoter appears to be much
more complex. Thus, we have identi®ed a region in the Bax
promoter with two Brn-3a response elements ¯anking the p53-
binding site. Mutation or deletion of either of these response
elements is insuf®cient to prevent Brn-3a repression of p53
inducibility whereas deletion or inactivation of both prevents
the effect. Hence, either of these elements is suf®cient for
blocking p53-mediated transactivation. However, such in-
activation is also sensitive to the nature of the p53-binding site
since substitution of this site with either site from the p21
promoter prevents the inhibitory effect of Brn-3a.
It is likely, therefore, that p53 binds in a particular
conformation to this Bax-binding site which allows it to
interact with Brn-3a bound at an adjacent site in such a
manner as to inhibit its transactivation potential. It is this
interaction and the precise arrangement of the sites that
Figure 9. Luciferase assay showing the response of a p21 promoter con-
struct containing the promoter from ±94 to +16 linked to the region of the
Bax promoter (±136 to ±42) containing the p53-binding site and the
downstream Brn-3a response element. The construct was co-transfected
either with empty expression vector (V) or with the same vector expressing
either p53 or Brn-3a. Values are the mean of at least three independent
determinations whose standard deviation is shown by the bars.
Figure 8. (A) Schematic diagram of Bax promoter constructs in which the p53-binding site (open box) has been replaced by either or both of the binding
sites from the p21 promoter (Bs1 and Bs2). (B) Luciferase assay showing the responses of the different promoter constructs when co-transfected with empty
expression vector (V) or the same vector expressing either p53 or Brn-3a. Values are the mean of at least three independent determinations whose standard
deviation is shown by the bars.



























































































 provides the Bax promoter with its characteristic inducibility
by p53 and inhibition of such inducibility by Brn-3a. It should
be noted, however, that these effects are not observed when
this element is transferred to the p21 promoter indicating that
the basal inducibility of this promoter by Brn-3a predominates
and that p53 bound to its site in the Bax promoter can co-
operate with Brn-3a under suitable circumstances.
Interestingly, reactivity with different anti-p53 antibodies
suggests that p53 may bind to the Bs1 site in the p21 promoter
differently compared to the Bs2 site or the site in the Bax
promoter (27,28).
As well as their different responses to Brn-3a, the Bax and
p21 promoters also differ in the region of Brn-3a that is
required for its effect on the promoter. Thus, the POU domain
of Brn-3a is suf®cient for activation of the p21 promoter as has
also been observed on several other promoters (10±12).
However, other regions of Brn-3a are required on the Bax
promoter since the POU domain alone does not produce
repression of p53-mediated transactivation. This effect is of
particular interest in view of the different functional activities
of the p21 and Bax proteins and their role in the response to
p53. Thus, the p21 factor is involved in growth arrest induced
by enhanced expression of p53 (17,18), whereas the Bax
protein is associated with its ability to induce apoptosis (19).
This is of particular interest since we have previously
demonstrated that the isolated POU domain of Brn-3a is
suf®cient to induce neuronal differentiation (10), whereas the
N-terminal domain of Brn-3a is required in addition to the
POU domain for its anti-apoptotic effect (13).
Over-expression of p53 in cells, for example, exposed to
DNA-damaging agents, can result in either cell cycle arrest
allowing the damage to be repaired or the induction of
apoptosis in cells which cannot repair the damage (29). Hence,
Brn-3a could act in these circumstances to promote p53-
mediated growth arrest via the synergistic activation of the
p21 promoter by Brn-3a and p53 and conversely block p53-
mediated apoptosis by inhibiting the p53-mediated transacti-
vation of the Bax promoter. Indeed, we have previously
demonstrated that cells over-expressing Brn-3a and p53
together show an enhanced rate of growth arrest and a reduced
rate of apoptosis compared to cells expressing p53 alone (16).
Such a role for Brn-3a would be opposite to that of the ASPP
factors which speci®cally stimulate the apoptotic activity of
p53 (30).
Therefore, by producing distinct effects of Brn-3a on p53-
mediated transactivation, the different architectures of the p21
and Bax promoters may play a key role in determining the
balance between growth arrest and apoptosis in cells over-
expressing p53. Moreover, the fact that the effect on the p21
promoter can be achieved by the isolated POU domain of Brn-
3a, whereas the effect on the Bax promoter cannot, provides an
additional level of regulation since Brn-3a exists in two
distinct forms both of which contain the POU domain but one
of which lacks the N-terminal domain required for the
anti-apoptotic effect of Brn-3a (31).
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